Valeant Pharmaceuticals International

Zelapar (selegiline HCl) Orally Disintegrating Tablets is a monoamine oxidase type-B (MAO-B) inhibitor approved on June 14, 2006 as a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.

For more prescribing information please visit zelapar.com

Valeant recently acquired Xcel Pharmaceuticals, a privately held specialty pharmaceutical company focused on neurology products in the United States.

The acquisition of Xcel expands Valeant's business in the U.S., enhances the company's neurology franchise with a highly specialized sales force, and adds retigabine, a novel Phase 3 compound, to the company's pipeline.

The largest products acquired in the purchase of Xcel are Diastat and Migranal.

TARIBAVIRIN and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries.